Prospects of antisense oligodeoxynucleotides to alleviate renal ischaemia-reperfusion injury.

Abstract

Renal ischaemia-reperfusion (I/R) injury is a clinically significant problem and an invariable consequence of renal transplantation. The problem begins at the onset of acute tubular necrosis (ATN), when the transplantation takes a long ischaemic interval by using the cardiac arrest donor's kidney. In addition, the longer the ischaemic interval, the higher the incidence rate of ATN. It is clinically important that renal I/R injury is reduced. The antisense oligodeoxynucleotide (AS-ODN), developed as a therapy for intractable diseases at the gene level, has recently been established as an important method in examining specific gene functions. The authors have previously demonstrated that AS-ODN/tissue factor (TF) prevents renal I/R injury. This review discusses the efficacy of AS-ODN/TF and AS-ODN/intercellular adhesion molecule-1 as existing targets, and the potential of AS-ODN/nuclear factor-kappaB, AS-ODN/cyclooxygenase and AS-ODN/5-lipoxygenase as prospective targets.

• Authors: Masahide Matsuyama, Rikio Yoshimura
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 4 Issue 12 Pg. 1931-7 (Dec 2004) ISSN: 1744-7682 [Electronic] England
• PMID: 15571455 (Publication Type: Journal Article, Review)

Chemical References

• Oligonucleotides, Antisense

Topics

• Animals
• Gene Targeting (methods)
• Humans
• Kidney (blood supply, drug effects, metabolism)
• Kidney Diseases (drug therapy, genetics, metabolism)
• Oligonucleotides, Antisense (administration & dosage, therapeutic use)
• Reperfusion Injury (drug therapy, genetics, metabolism)